<DOC>
	<DOCNO>NCT00418548</DOCNO>
	<brief_summary>The purpose study compare efficacy , pharmacokinetics , safety investigational formulation etanercept administer 50 mg weekly 25 mg twice weekly placebo patient ankylose spondylitis ( AS ) .</brief_summary>
	<brief_title>Study Comparing Etanercept 50 mg Once Weekly 25 mg Twice Weekly Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis AS , define Modified New York Criteria Ankylosing Spondylitis . Active AS , define average visual analog scale ( VAS ) ≥ 30 duration intensity morning stiffness least 2 follow : VAS patient global assessment ≥ 30 ; average VAS nocturnal total pain ≥ 30 ; BASFI ≥ 30 ( score scale 0 100 ) . Complete ankylosis ( fusion ) spine . Previous treatment etanercept , antibody Tumor Necrosis Factor α ( TNFα ) , TNFα inhibitor biologic agent . Use disease modify antirheumatic drug ( DMARDs ) hydroxychloroquine , sulphasalazine , methotrexate within 4 week baseline . Subjects treat hydroxychloroquine , sulphasalazine , methotrexate may continue drug study dos must hold stable 4 week baseline examination duration study . Receipt multiple nonsteroidal antiinflammatory drug ( NSAIDs ) baseline . Dose NSAID change within 2 week baseline evaluation . Dose prednisone &gt; 10 mg/day ( equivalent ) change within 2 week baseline evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>